Activated Probiotics Biome Acne Probiotic

Ailments

• Acne
• Skin Redness
• Test

Instructions For Use

Adults and children over 2 years:

Take 1 capsule daily (with or without food), or as directed by your healthcare practitioner.

Ingredients

No Added

GMOs, wheat, gluten, dairy, lactose, fructose, yeast, nuts, seeds, peanuts, soy, egg, fish, shellfish, or animal derivatives.

No artificial colours, flavours, sweeteners, or preservatives.

Suitable for vegetarians and vegans.

Warnings and Cautions

If symptoms persist, talk to your healthcare practitioner.

Storage Conditions

Refrigeration Not Required

Technical Information

ACNE VULGARIS

Acne is a highly prevalent inflammatory skin disorder, affecting approximately 80% of adolescents and young adults aged 11 to 30 years1, 2. Due to the appearance of lesions and scarring, acne is associated with significant mental health impacts, such as anxiety, depression, social inhibition and impaired self-esteem, all of which improve with effective treatment1, 3.

INFLAMMATION AND SKIN DYSBIOSIS IN ACNE

Acne is an inflammatory disease of the pilosebaceous unit (PSU), the hair follicle and associated oil glands, which involves various immunochemical pathways and secondary overgrowth of Cutibacterium acnes4. In acne, various underlying metabolic and inflammatory mediators drive excessive sebum (oil) production and induce hyperproliferation of skin cells, creating blocked PSUs and the formation of early acne lesions (comedones)4. These structural changes within the PSU facilitate opportunistic overgrowth of C. acnes and create a dysbiotic skin environment that triggers immune-mediated inflammatory responses and the highly inflammatory lesions (papules, pustules, etc.) characteristic of acne5.

C. ACNES AND PROGRESSION OF ACNE LESIONS

C. acnes (previously known as Propionibacterium acnes) is an opportunistic resident of the skin microbiome that exacerbates acne severity when conditions allow for its overgrowth1, 5. Proliferation of C. acnes stimulates a pro-inflammatory immune response and promotes the progression of comedones into more inflammatory acne lesions1. Increasing concentrations of metabolites produced by C. acnes in the skin, such as lipases and chemotactic factors, elicit the generation of free radicals and skin cell damage1.

These effects promote further keratinocyte proliferation and the production of more inflammatory sebum via oxidation of its lipid contents, increasing the comedogenic potential of the skin and worsening the severity of acne1, 6. Controlling overgrowth of C. acnes, and addressing underlying metabolic and inflammatory mediators of blocked PSUs, can assist in the reduction of acne symptoms.

THE ROLE OF THE GUT MICROBIOTA AND SPECIFIC PROBIOTICS

The health of the gut microbiota is thought to influence skin health and the development of acne through its effects on the immune system and systemic inflammation, as well as its interactions with the skin microbiome through the production of antimicrobial metabolites which enter circulation and accumulate in the skin5.

Studies on individuals with acne have demonstrated unfavourable gut microbiota compositions, with lower microbial diversity and a higher ratio of Bacteroidetes to Firmicutes, which may predispose these individuals to immune dysregulation, greater inflammatory responses and thus acne5.

Specific probiotic strains are being investigated for their ability to harness the links that exist between the gut microbiome, systemic inflammatory processes, and the skin microbiome. For example, in-vitro studies have demonstrated that Lactobacillus salivarius LS03 can inhibit the growth of C. acnes and reduce the production of key inflammatory cytokines in response to its opportunistic growth (1).

Following on from this promising mechanistic research, LS03 formed the basis of a probiotic combination that has been clinically trialled for the treatment of acne; a combination of Lactobacillus salivarius LS03 (1 BLB*), Lactobacillus casei LC03 (0.5 BLB*) and Bifidobacterium breve BR03 (0.5 BLB*).

HUMAN CLINICAL TRIAL

In one arm of this recently published double-blind, randomised, placebo-controlled trial, subjects with mild to moderate acne received this probiotic formulation once a day for 8 weeks7. At week 4, there was a statistically significant (p < 0.05) decrease in the number of acne lesions in the subjects taking the probiotic (-31.11%) compared to placebo (-10%), measured using the global acne grading system (GAGS) score (see Figure 1).

This continued to improve after 8 weeks (-38.89% vs 18.89%, p < 0.05). Significant reductions in skin redness (T0 1.82 ± 0.06 vs T2 0.73 ± 0.74, p < 0.05) (see Figure 2) and  relative abundance of C. acnes (26.8 vs 21.7 log RA, p < 0.01) on the skin were observed following the use of this probiotic supplement for 8 weeks, as were significant reductions in sebum production.

References

1. Deidda F, Amoruso A, Nicola S, Graziano T, Pane M, Mogna L. New Approach in Acne Therapy A Specific Bacteriocin Activity and a Targeted Anti IL-8 Property in Just 1 Probiotic Strain, the L. salivarius LS03. J Clin Gastroenterol. 2018 Nov 1;52:S78–81.

2. Dréno, B., Dagnelie, M. A., Khammari, A., & Corvec, S. (2020). The Skin Microbiome: A New Actor in Inflammatory Acne. American journal of clinical dermatology, 21(Suppl 1), 18–24.

3. Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012;379:361–72.

4. Tanghetti, Emil. A. (2013). The role of inflammation in the pathology of acne. Journal of Clinical and Aesthetic Dermatology, 6(9), 16–24.

5. Lee, Byun, & Kim. (2019). Potential Role of the Microbiome in Acne: A Comprehensive Review. Journal of Clinical Medicine, 8(7)

6. Jourdan, E., Trompezinski, S., Weber, S., Cadars, B., Larue, F., Ardiet, N., Chavagnac-Bonneville, M., & Sayag, M. (2016). Assessment of a new biological complex efficacy on dysseborrhea, inflammation, and Propionibacterium acnes proliferation. Clinical, Cosmetic and Investigational Dermatology, Volume 9, 233–239.

7. Rinaldi, F., Marotta, L., Mascolo, A., Amoruso, A., Pane, M., Giuliani, G., & Pinto, D. (2022). Facial Acne: A Randomized, Double-Blind, Placebo-Controlled Study on the Clinical Efficacy of a Symbiotic Dietary Supplement. Dermatology and Therapy.